Skip to main content
Erschienen in: World Journal of Surgery 10/2010

01.10.2010

Is Hypoalbuminemia an Independent Prognostic Factor in Patients with Gastric Cancer?

verfasst von: Andrew B. C. Crumley, Robert C. Stuart, Margaret McKernan, Donald C. McMillan

Erschienen in: World Journal of Surgery | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Studies have indicated that hypoalbuminemia is associated with decreased survival of patients with gastric cancer. However, the prognostic value of albumin may be secondary to an ongoing systemic inflammatory response. The aim of the study was to assess the relation between hypoalbuminemia, the systemic inflammatory response, and survival in patients with gastric cancer.

Methods

Patients diagnosed with gastric carcinoma attending the upper gastrointestinal surgical unit in the Royal Infirmary, Glasgow between April 1997 and December 2005 and who had a pretreatment measurement of albumin and C-reactive protein (CRP) were studied.

Results

Most of the patients had stage III/IV disease and received palliative treatment. The minimum follow-up was 15 months. During follow-up, 157 (72%) patients died of their cancer. On univariate analysis, stage (p < 0.001), treatment (p < 0.001), albumin level (p < 0.001), and CRP level (p < 0.001) were significant predictors of survival. On multivariate analysis, stage (p < 0.001), treatment (p < 0.001), and CRP level (p < 0.001) remained significant predictors of survival. Albumin was no longer an independent predictor of survival.

Conclusions

Low albumin concentrations are associated with poorer survival in patients with gastric cancer. However, the strength of this relation with survival is dependent on the presence of a systemic inflammatory response, as evidenced by an elevated CRP level. Therefore, it appears that the relation between hypoalbuminemia and poor survival is secondary to that of the systemic inflammatory response.
Literatur
2.
Zurück zum Zitat Allgayer H, Heiss MM, Schildberg FW (1997) Prognostic factors in gastric cancer. Br J Surg 84:1651–1664CrossRefPubMed Allgayer H, Heiss MM, Schildberg FW (1997) Prognostic factors in gastric cancer. Br J Surg 84:1651–1664CrossRefPubMed
3.
Zurück zum Zitat Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591PubMed Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591PubMed
4.
Zurück zum Zitat Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996–2004CrossRefPubMed Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996–2004CrossRefPubMed
5.
Zurück zum Zitat Lien YC, Hsieh CC, Wu YC et al (2004) Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg 8:1041–1048CrossRefPubMed Lien YC, Hsieh CC, Wu YC et al (2004) Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg 8:1041–1048CrossRefPubMed
6.
Zurück zum Zitat Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D et al (2007) Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 14:381–389CrossRefPubMed Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D et al (2007) Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 14:381–389CrossRefPubMed
7.
Zurück zum Zitat Alici S, Kaya S, Izmirli M et al (2006) Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sci Monit 12:CR221–CR229PubMed Alici S, Kaya S, Izmirli M et al (2006) Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sci Monit 12:CR221–CR229PubMed
8.
Zurück zum Zitat Lee J, Lim T, Uhm JE et al (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886–891CrossRefPubMed Lee J, Lim T, Uhm JE et al (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886–891CrossRefPubMed
9.
Zurück zum Zitat Onate-Ocana LF, Becker M, Carrillo JF et al (2008) Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol 98:336–342CrossRefPubMed Onate-Ocana LF, Becker M, Carrillo JF et al (2008) Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol 98:336–342CrossRefPubMed
10.
Zurück zum Zitat McMillan DC, Crozier JE, Canna K et al (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881–886CrossRefPubMed McMillan DC, Crozier JE, Canna K et al (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881–886CrossRefPubMed
11.
Zurück zum Zitat Al Murri AM, Bartlett JM, Canney PA et al (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227–230CrossRefPubMed Al Murri AM, Bartlett JM, Canney PA et al (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227–230CrossRefPubMed
12.
Zurück zum Zitat Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030CrossRefPubMed Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030CrossRefPubMed
13.
Zurück zum Zitat Glen P, Jamieson NB, McMillan DC et al (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6:450–453CrossRefPubMed Glen P, Jamieson NB, McMillan DC et al (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6:450–453CrossRefPubMed
14.
Zurück zum Zitat McMillan DC, Watson WS, O’Gorman P et al (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39:210–213CrossRefPubMed McMillan DC, Watson WS, O’Gorman P et al (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39:210–213CrossRefPubMed
15.
Zurück zum Zitat Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459CrossRefPubMed Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459CrossRefPubMed
16.
Zurück zum Zitat Maltoni M, Caraceni A, Brunelli C et al (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations: a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240–6248CrossRefPubMed Maltoni M, Caraceni A, Brunelli C et al (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations: a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240–6248CrossRefPubMed
17.
Zurück zum Zitat Ellegard LH, Bosaeus IG (2008) Biochemical indices to evaluate nutritional support for malignant disease. Clin Chim Acta 390:23–27CrossRefPubMed Ellegard LH, Bosaeus IG (2008) Biochemical indices to evaluate nutritional support for malignant disease. Clin Chim Acta 390:23–27CrossRefPubMed
18.
Zurück zum Zitat McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67:257–262CrossRefPubMed McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67:257–262CrossRefPubMed
19.
Zurück zum Zitat Morley JE, Thomas DR, Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735–743PubMed Morley JE, Thomas DR, Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735–743PubMed
20.
Zurück zum Zitat Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345–1350PubMed Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345–1350PubMed
21.
Zurück zum Zitat Ashizawa T, Okada R, Suzuki Y et al (2005) Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8:124–131CrossRefPubMed Ashizawa T, Okada R, Suzuki Y et al (2005) Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8:124–131CrossRefPubMed
22.
Zurück zum Zitat Liao WC, Lin JT, Wu CY et al (2008) Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 14:428–434CrossRefPubMed Liao WC, Lin JT, Wu CY et al (2008) Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 14:428–434CrossRefPubMed
23.
Zurück zum Zitat Ikeguchi M, Hatada T, Yamamoto M et al (2009) Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12:95–100CrossRefPubMed Ikeguchi M, Hatada T, Yamamoto M et al (2009) Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12:95–100CrossRefPubMed
24.
Zurück zum Zitat Kim DK, Oh SY, Kwon HC et al (2009) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9:155CrossRefPubMed Kim DK, Oh SY, Kwon HC et al (2009) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9:155CrossRefPubMed
25.
Zurück zum Zitat Xu CY, Shen JG, Shen JY et al (2009) Ulcer size as a novel indicator marker is correlated with prognosis of ulcerative gastric cancer. Dig Surg 26:312–316CrossRefPubMed Xu CY, Shen JG, Shen JY et al (2009) Ulcer size as a novel indicator marker is correlated with prognosis of ulcerative gastric cancer. Dig Surg 26:312–316CrossRefPubMed
26.
Zurück zum Zitat Deans DA, Wigmore SJ, de Beaux AC et al (2007) Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br J Surg 94:1501–1508CrossRefPubMed Deans DA, Wigmore SJ, de Beaux AC et al (2007) Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br J Surg 94:1501–1508CrossRefPubMed
27.
Zurück zum Zitat Crumley AB, Stuart RC, McKernan M et al (2010) Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg 14:781–787CrossRefPubMed Crumley AB, Stuart RC, McKernan M et al (2010) Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg 14:781–787CrossRefPubMed
Metadaten
Titel
Is Hypoalbuminemia an Independent Prognostic Factor in Patients with Gastric Cancer?
verfasst von
Andrew B. C. Crumley
Robert C. Stuart
Margaret McKernan
Donald C. McMillan
Publikationsdatum
01.10.2010
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 10/2010
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-010-0641-y

Weitere Artikel der Ausgabe 10/2010

World Journal of Surgery 10/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.